• O. ROTAR Bukovinian State Medical University, Chernivtsi, Ukraine
  • I. KHOMIAK “O. O. Shalimov” National Institute of Surgery and Transplantology, Kyiv, Ukraine
  • V. ROTAR Bukovinian State Medical University, Chernivtsi, Ukraine
  • A. KHOMIAK “O. O. Shalimov” National Institute of Surgery and Transplantology, Kyiv, Ukraine
  • V. SHAFRANIUK Bukovinian State Medical University, Chernivtsi, Ukraine
  • O. POLIANSKY Bukovinian State Medical University, Chernivtsi, Ukraine


Acute necrotizing pancreatitis (ANP) is potentially lethal inflammatory process. Recent researches established that presence of multiorgan failure together with pancreatic infection are major determinants of its mortality. But significance of acute gastrointestinal injury (AGI) in course of ANP is still remaining unclear. Aim: To determine frequency and significance of AGI on severity and mortality of ANP. Material and methods: We performed a prospective observational cohort study of 151 patients with ANP which were admitted to single intensive care department. AGI was established according to European Society of Intensive Care Medicine (ESICM) recommendations. Clinical and laboratorial variables as well as plasma citrulline concentrations were studied. Results: Persistent organ failure was diagnosed in 33% and transient in 67% observations. Respiratory failure has been dominated in mortality structure, cardiovascular, renal and intestinal failures were met with equal frequency. Serum citrulline concentration reflected the level of AGI. Conclusions:  Intestinal failure is strongly associated with unfavorable events in patients with acute necrotizing pancreatitis as well as pulmonary, cardiovascular and renal dysfunctions. Plasma citrulline concentration is simple and reliable marker for diagnosing and monitoring AGI.


1. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143(5): 1179-1187.
2. Alsfasser G, Schwandner F, Pertschy A, Hauenstein K, Foitzik T, Klar E. Treatment of necrotizing pancreatitis: redefining the role of surgery. World J Surg 2012; 36: 1142-1147.
3. Van-Santyoort HC, Besselink MG, et al. A Step-up approach or open necrosectomy for necrotizing pancreatitis. New Engl J Med 2010; 362: 1491-1502.
4. Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut 2004; 53: 1340-1344.
5. De Beaux AC, Palmer KR, Carter DC. Factors influencing morbidity and mortality in acute pancreatitis; an analysis of 279 cases. Gut 1995; 37: 121-126.
6. Perez A, Whang EE, Brooks DC, et al. Is severity of necrotizing pancreatitis increased in extended necrosis and infected necrosis? Pancreas 2002; 25: 229-233.
7. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 1992; 216: 117-134.
8. Al-Bahrani AZ, Darwish A, Hamza N, Benson J, Eddleston JM, Snider RH. Gut barrier dysfunction in critically ill surgical patients with abdominal compartment syndrome. Pancreas 2010; 39: 1064-1069.
9. Reintam Blaser A, Malbrain ML, Starkopf J, et al. Gastrointestinal function in intensive care pa-tients:terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems. Intensive Care Med 2012; 38: 384-394.
10. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis 2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-111.
11. Sloss A, Kubler P. Prescribing in liver disease. Aust Prescr 2009; 32: 32-35.
12. Hecker A, Hecker B, Hecker M, Riedel JG, Weigand MA, Padberg W. Acute abdominal compartment syndrome: current diagnostic and therapeutic options. Langenbecks Arch Surg 2016; 401: 15-24.
13. Boyde TR. Optimization conditions for the colorimetric determination of citrulline using diacetyl-monoxime. Anal Biochem 1980; 107: 424-431.
14. Piton G, Manzon C, Cypriani B, Carbonnel F, Capellier G. Acute intestinal failure critically ill patients: is plasma citrulline right market? Intensive Care Med 2011; 37: 911-917.
15. Blasco Alonso J, Serrano Nieto J, Navas López VM, et al. Plasma citrulline as a marker of loss of enterocitary mass in coeliac disease in childhood. Nutr Hosp 2011; 26: 807-813.
16. Diamanti A, Panetta F, Gandullia P, et al. Plasma citrulline as marker of bowel adaptation in children with short bowel syndrome. Langenbecks Arch Surg 2011; 396: 1041-1046.
17. Barzał JA, Szczylik C, Rzepecki P, Jaworska M, Anuszewska E. Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage. Acta Biochim Pol 2014; 61: 615-631.
18. Lee EH, Ko JS, Seo JK. Correlations of plasma citrulline levels with clinical and endoscopic score and blood markers according to small bowel involvement in pediatric Crohn disease. J Pediatr Gas-troenterol Nutr 2013; 57: 570-575.